Cost-effectiveness evaluation of a quadrivalent human papillomavirus vaccine in Belgium

PharmacoEconomics

Volumn 27, Issue 3, 2009, Pages 231-245

  Annemans, Lieven ^a   Rémy, Vanessa ^b   Oyee, James ^c   Largeron, Nathalie ^b  

^a GHENT UNIVERSITY   (Belgium)

^b SANOFI PASTEUR   (France)

^c MAPI VALUES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; AGED; ARTICLE; BELGIUM; CANCER IMMUNIZATION; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CHILD; COHORT ANALYSIS; CONDYLOMA ACUMINATUM; COST EFFECTIVENESS ANALYSIS; DEATH; DRUG EFFICACY; FEMALE; HEALTH CARE COST; HEALTH PROGRAM; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROBABILITY; PUBLIC HEALTH SERVICE; SCHOOL CHILD; SENSITIVITY ANALYSIS; UTERINE CERVIX CANCER;

BELGIUM; CHILD; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; FEMALE; HUMANS; MARKOV CHAINS; MASS IMMUNIZATION; MODELS, ECONOMIC; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES;

EID: 64749106034     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200927030-00006     Document Type: Article

References (59)

1. Schiffman M, Castle PE, Jeronimo J, et al. Human papillomavirus and cervical cancer. Lancet 2007; 370 (9590): 890-907
2. Belgian Cancer Registry. Annual statistics since 1999: 2003-F-BEL-Lft [online]. Available from URL: http://www.registreducancer.org [Accessed 2007 Sep 5]
3. Smith JS, Lindsay L, Hoots B, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007; 121 (3): 621-32
4. Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med 1997; 102 (5A): 3-8
5. WHO/ICO Information Centre on HPV and Cervical Cancer (HPV Information Centre). Summary report on HPV and cervical cancer statistics in Belgium: 2007 [online]. Available from URL: http://www.who.int/hpvcentre [Accessed 2007 Sep 4]
6. Beutner KR, Wiley DR. Recurrent external genital warts: a literature review. Papillomavirus Rep 1997; 8: 69-74
7. McMillan A. The management of difficult anogenital warts. Sex Transm Dis 1999; 75: 192-4
8. Family Planning Association (FPA). Factsheet on sexually transmitted infections, August 2007: genital warts [online]. Available from URL: http://www.fpa.org.uk/information/factsheets [Accessed 2007 Oct 1]
9. Bray F, Sankila R, Ferlay J, et al. Estimates of cancer incidence and mortality in Europe in 1995. Eur J Cancer 2002; 38(1): 99-166
10. Arbyn M., Van Oyen H. Analysis of individual health insurance data pertaining to pap smears, colposcopies, biopsies and surgery on the uterine cervix (Belgium, 1996-2000). [SIPH/EPI reports N 2004-021]. Brussels: Scientific Institute of Public Health, 2004 [online]. Available from URL: http://www.iph.fgov.be/epidemio/epien/cervixen/intermut.pdf [Accessed 2009 Feb 16]
11. Thiry N, Lambert ML, Cleemput I, et al. Vaccination HPV pour la prévention du cancer du col de l'utérus en Belgique. Health Technology Assessment (HTA) [KCE reports 64B]. Bruxelles: Centre Fédéral d'Expertise des Soins de Santé (KCE), 2007
12. European Medicines Agency (EMEA). Gardasil European public assessment report (EPAR) [online]. Available from URL: http://www.emea.europa.eu/humandocs/ Humans/EPAR/gardasil [Accessed 2007 Sep 5]
13. The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356 (19): 1915-27
14. Garland SM, Hernandez-Avila M, Wheeler CM., et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356 (19): 1928-43
15. Joura EA, Leodolter S, Hernandez-Avila M, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 2007; 369 (9574): 1693-702
16. Kulasingam SL, Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 2003; 290 (6): 781-9
17. Myers ER, McCrory DC, Nanda K, et al. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol 2000; 151 (12): 1158-71
18. Bergeron C, Largeron N, McAllister R, et al. Costeffectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France. Int J Technol Assess Health Care 2008; 24 (1): 10-9
19. Kulasingam SL, Benard S, Barnabas RV, et al. Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: a cost-effectiveness analysis. Cost Eff Resour Alloc 2008; 6: 4
20. Weinstein MC, O'Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices - modeling studies. Value Health 2003; 6(1): 9-17
21. Cleemput I, Van Wilder P, Vrijens F, et al. Recommandations pour les évaluations pharmacoéconomiques en Belgique. Health Technology Assessment (HTA) [KCE reports 38B]. Bruxelles: Centre fédéral d'expertise des soins de santé (KCE), 2008
22. Brisson M., Van de Velde N, De Wals P, et al. Estimating the number needed to vaccinate to prevent diseases and death related to human papillomavirus infection. CMAJ 2007; 177 (5): 464-8
23. Canfell K, Barnabas R, Patnick J, et al. The predicted effect of changes in cervical screening practice in the UK: results from a modelling study. Br J Cancer 2004; 91 (3): 530-6
24. Siebert U, Sroczynski G, Hillemanns P, et al. The German cervical cancer screening model: development and validation of a decision-analytic model for cervical cancer screening in Germany. Eur J Public Health 2006; 16 (2): 185-92
25. Cancer Research UK. Cervical cancer statistics for the UK: 2003 [online]. Available from URL: http://infb.cancerresearchuk.org/cancerstats/types/cervix/? a = 5441 [Accessed 2007 Sep 5]
26. Flemish Cancer Registry Network. Cancer incidence and survival in Flanders 2000-2001 [online]. Available from URL: http://www.tegenkanker.net/ uploadedfiles/Kanker registratie/Kankerincid.ntie/2000-2001 [Accessed 2007 Sep 5]
27. WHO. WHO Statistical Information System 2004 [online]. Available from URL: http://www.who.int/whosis/en/index.html [Accessed 2007 Sep 5]
28. Arbyn M, Van Oyen H. SFTFMG: description of the influence of age, period and cohort effects on cervical cancer mortality by loglinear poisson models (Belgium, 1955-94). Arch Public Health 2002; 60 (2): 73-100
29. De Schrijver K. Epidemiologie van seksueel overdraagbare ziekten in België. Epidemiologisch bulletin van de Vlaamse gemeenschap 2003; 45 (3) [online]. Available from URL: http://www.zorg-en-gezondheid.be/defaultSubsite. aspx?id= 9936 [Accessed 2009 Feb 16]
30. Monsonégo J, Breugelmans JG, Bouée S, et al. Anogenital warts incidence, medical management and costs in women consulting gynaecologists in France [in French], Gynecol Obstet Fertil 2007; 35 (2): 107-13
31. Belgian Society of Clinical Cytology. Belcyto 2007 [online]. Available from URL: http://www.belcyto.ulg.ac.be/ [Accessed 2007 Sep 7]
32. Arbyn M, De Cock R, et al. A. technical guideline: collection of adequate pap smears of the uterine cervix. Brussels: Flemish Steering Group on Cervical Cancer Screening, Ministry of the Flemish Community Department of Public Health, 2001
33. Mitchell MF, Schottenfeld D, Tortolero-Luna G, et al. Colposcopy for the diagnosis of squamous intraepithelial lesions: a meta-analysis. Obstet Gynecol 1998; 91 (4): 626-31
34. ANAES. Recommandations pour la practice clinique: conduite à tenir devant une patiente ayant un frottis cervico-utérin anormal 1998 et Actualisation 2002 Sep [online]. Available from URL: http://www.has-sante.fr/ portail/jcms/c-469254/conduite-a-tenir-devant-un-frottis-anormaldu-col-de-1- uterus [Accessed 2009 Feb 16]
35. Arbyn M, Buntinx F, Van Ranst M, et. al. Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. J Natl Cancer Inst 2004; 96 (4): 280-93
36. Karnon J, Peters J, Platt J, et al. Liquid-based cytology in cervical screening: an updated rapid and systematic review and economic analysis. Health Technol Assess 2004; 8 (20): iii, 1-78
37. Clifford GM, Smith JS, Aguado T, et al. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer 2003; 89 (1): 101-5
38. Clifford GM, Rana RK, Franceschi S, et al. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev 2005; 14 (5): 1157-64
39. Villa L. Quadrivalent human papillomavirus (HPV) type 6/11/16/18 L1 virus-like particle vaccine: first analysis of cross-protection against cervical intraepithelial neoplasia (CIN) and adenocarcinoma in situ (AIS) caused by oncogenic HPV types in addition to 16/18. 7th International Multidisciplinary Congress: European Research Organization on Genital Infection and Neoplasia (EUROGIN); 2007 Oct 4-6; Monte Carlo
40. Villa LL, Costa RL, Petta CA, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006; 95 (11): 1459-66
41. Olsson SE, Villa LL, Costa RLR, et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 2007; 25 (26): 493.1-9
42. Van Damme P, Theeten H, Hoppenbrouwers K, et al. Studie van de vaccinatiegraad bij jonge kinderen en adolescenten in Vlaanderen in 2005. Brussels: Ministerie Van De Vlaamse Gemeenschap, Departement Welzijn, Volksgezondheid en Cultuur Administratie Gezondheidszorg; March 2006 [online]. Available from URL: http://www.wvc.vlaanderen. be/vaccinatie/documentatie/ rapport-couverturestudie.pd.f [Accessed 2007 Sep 5]
43. Myers ER, Green SL. Patient preferences for health states related to HPV infection: visual analogue scales vs time trade-off elicitation [abstract no. 390.2]. Proceedings of the 21st International Papillomavirus Conference; 2004 Feb 20-26; Mexico City
44. Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis 2007; 13(1): 28-41
45. RIZIV-INAMI. National Institute of Health Insurance and Invalidity of Belgium [online]. Available from URL: http://www.inami.fgov.be/ [Accessed 2007 Sep 5]
46. Annemans L, Remy V, Lamure E, et al. Economic burden associated with the management of cervical cancer, cervical dysplasia and genital warts in Belgium. J Med Econ 2008; 11:135-50
47. Moniteur Belge. Oct 19th 2007, version 3, page 54500 [online]. Available from URL: http://www.ejustice.just.fgov.be/ [Accessed 2009 Feb 16]
48. Goldie SJ, Kohli M, Grima D, et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 2004; 96 (8): 604-15
49. Ferlay J, Bray F, Pisani P, et al. Globocan 2002: cancer incidence, mortality and prevalence worldwide. Lyon: IARC Press, 2004
50. National Institute for Clinical Excellence. Guide to the methods of technology appraisal. London: NICE, 2004 [online]. Available from URL: http://www.nice.org.uk/aboutnice/howwework/devnicetech/technologyappraisal processguides/guide-to-the-methods-of-technologyappraisal-reference-n0515.jsp [Accessed 2009 Feb 16]
51. Towse A, Pritchard C. National Institute for Clinical Excellence (NICE): is economic appraisal working? Pharmacoeconomics 2002; 20 Suppl. 3: 95-105
52. Conseil supérieur de la santé. Vaccination contre les infections causées par le papillomavirus humain: 2 mai 2007 [online]. Available from URL: https://portal.health.fgov.be/portal/page?-pageid=56, 512429&-dad=portal&-schema= PORTAL [Accessed 2007 Sep 5]
53. The UK Collaborative Group for HIV and STI Surveillance. Testing times: HIV and other sexually transmitted infections in the United Kingdom: London: Health Protection Agency, Centre for Infections. November 2007 [online]. Available from URL: http://www.hpa.org.uk/web/HPAweb& HPAwebStandard/HPAweb- C/1203084355941 [Accessed 2009 Feb 16]
54. Dasbach EJ, Elbasha EH, Insinga RP. The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK. BJOG 2008; 115 (8): 947-56
55. Chesson HW, Ekwueme DU, Saraiya M, et al. Costeffectiveness of human papillomavirus vaccination in the United States. Emerg Infect Dis 2008; 14 (2): 244-51
56. Brisson M, Van de Velde N, De Wals P, et al. The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada. Vaccine 2007; 25 (29): 5399-408
57. Kim SY, Goldie SJ. Cost-effectiveness analyses of vaccination programmes: a focused review of modelling approaches. Pharmacoeconomics 2008; 26 (3): 191-215
58. Dasbach EJ, Elbasha EH, Insinga RP. Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease. Epidemiol Rev 2006; 28: 88-100
59. Moniteur Belge. 2008 Nov 20, version 2: pp 61781 [online]. Available from URL: http://www.ejustice.just.fgov.be/[Accessed 2009 Feb 16]